Phaseline

Companies › Zhejiang Haichang Biotech

Zhejiang Haichang Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WGI-0301
Antisense oligonucleotide complementary to Akt-1 mRNA
AKT1Phase 2Advanced Hepatocellular Carcinoma (HCC)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06309485WGI-0301Phase 2Advanced Hepatocellular Carcinoma (HCC)OncologyDec 2026

Targets

AKT1 (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) Roche Laekna Alterome Therapeutics Atavistik Bio

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.